ANSTO Health News

Four million nuclear medicine doses produced


ANSTO has produced its four millionth patient dose of Australian nuclear ‎medicine‚Ĩ, which is used to diagnose a wide range of illnesses, including cardiac conditions, cancers and skeletal injuries

Ground floor of new ANM facility nears completion


Australia’s new nuclear medicine manufacturing facility is taking shape. This project which will enable Australia to help meet world demand for the most common radionuclide used in nuclear medicine, Molybdenum-99. 

 

About ANSTO Health

ANSTO Health's core mission is to manufacture and advance the use of radiopharmaceuticals which will improve the health of Australians. Through its TGA-licensed facilities south of Sydney, ANSTO Health supplies more than 85 per cent of nuclear medicine to 250 hospitals and medical practices across Australia.

 
 
 

 

Doing business with us

Products and pricing: For enquiries about specific product information, please contact ANSTO Health on: 

Phone: 1800 251 572, or email: health@ansto.gov.au
 
Finance: For account enquiries and other related topics email: deanne.wood@ansto.gov.au
 
Compliance and quality: For enquiries email: louise.foot@ansto.gov.au
 
Safety: For enquiries email: samantha.arkawpaw@ansto.gov.au
 
Regulatory affairs:  For enquiries email: amandeep.sharma@ansto.gov.au
 
Operations: For enquiries email: mark.moore@ansto.gov.au

 

Customer service contacts

 

Australian customers: Phone: 1800 251 572. Fax: 1800 648 132
 
International customers: Phone: + 61 2 9717 9992. Fax: + 61 2 9543 6511
 
Street address: New Illawarra Road, Lucas Heights, NSW, Australia
 
Email address: health@ansto.gov.au